Therapeutic agents for achondroplasia
CA 2398030 C · Owner: Nakao, Kazuwa · Inventors: Nakao, Kazuwa
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention aims to provide novel therapeutic agents for achondroplasia caused by mutations in FGFR3. Therapeutic agents for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3) comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient are disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 14, 2002 and granted May 24, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 14, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 14, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.